Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.

Inclusion Criteria:

• Patients ≥ 19 years old
• Patients who received new generation sirolimus-eluting (Osiro®) stent implantation for treating ACS
• Patients without significant clinical events such as MI, stent thrombosis or revascularization until 3 months after PCI
• Provision of informed consent

Exclusion Criteria:

• Age > 80 years
• Increased risk of bleeding, anemia, thrombocytopenia
• A need for oral anticoagulation therapy
• Pregnant women or women with potential childbearing
• Life expectancy < 1 year
• Patients who treated with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, or atazanavir)
• Patients who had history of intracranial hemorrhage
• Moderate to severe hepatic dysfunction
• Increased risk of bradycardia-related symptom (Guidance and reference)